Brokerages expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report earnings per share (EPS) of ($0.52) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from ($0.60) to ($0.45). Kala Pharmaceuticals posted earnings per share of ($0.46) during the same quarter last year, which would indicate a negative year over year growth rate of 13%. The company is expected to report its next quarterly earnings results on Monday, March 25th.
On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.20) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($2.11). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.39) per share, with EPS estimates ranging from ($2.84) to ($2.03). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.01).
Shares of NASDAQ:KALA traded up $0.14 on Monday, reaching $6.65. 124,700 shares of the company were exchanged, compared to its average volume of 203,480. The company has a quick ratio of 6.27, a current ratio of 6.34 and a debt-to-equity ratio of 0.30. Kala Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $18.30. The stock has a market cap of $217.17 million, a PE ratio of -1.14 and a beta of 1.30.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Trexquant Investment LP acquired a new stake in Kala Pharmaceuticals in the 3rd quarter valued at about $140,000. Rhumbline Advisers acquired a new stake in Kala Pharmaceuticals in the 4th quarter valued at about $75,000. Virtu Financial LLC acquired a new stake in Kala Pharmaceuticals in the 3rd quarter valued at about $200,000. Bradley Foster & Sargent Inc. CT acquired a new stake in Kala Pharmaceuticals in the 4th quarter valued at about $115,000. Finally, Engineers Gate Manager LP acquired a new stake in Kala Pharmaceuticals in the 3rd quarter valued at about $249,000. 48.38% of the stock is currently owned by hedge funds and other institutional investors.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
See Also: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.